Advertisement

Transcriptional Regulation

  • Kathleen W. Scotto
  • Tan A. Ince

Abstract

The eukaryotic cell is remarkably versatile. Whether it is destined to spend its existence producing antibodies for immune response or moving mucus over the epithelial sheets of the colon is determined by the myriad of proteins that it manufactures. Some processes are shared by all cells. Therefore, most cells contain a subset of common proteins, including proteins involved in forming the cytoskeleton, proteins intrinsic to the membranes of the golgi and endoplasmic reticulum, ribosomal proteins, and other “housekeeping proteins.” In contrast, subsets of proteins are expressed only in specialized cells, where they serve specific and often unique functions. Cellular specialization is controlled by gene expression, in which groups of genes are activated or repressed in response to internal and external stimuli. Moreover, the integrity with which gene expression is controlled can determine whether a cell performs its function in harmony and collaboration with its surroundings or defies the controls of growth and proliferation and invades territories normally reserved for other cells, resulting in malignancy.

Keywords

Acute Myeloid Leukemia Glucocorticoid Receptor Acute Promyelocytic Leukemia Scription Factor TATA Motif 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lewin B: Genes V. New York: Oxford University Press; 1994.Google Scholar
  2. 2.
    Raven PH, Johnson GB: Biology, edn 4. Boston: Wm.C. Brown Publishers; 1996: 349–370.Google Scholar
  3. 3.
    Pugh F, Tjian R: Diverse transcriptional functions of the multisubunit eukaryotic TFIID complex. J Biol Chem 1992, 267: 679–682.PubMedGoogle Scholar
  4. 4.
    Orphanides G, Lagrange T, Reinberg D: The general transcription factors of RNA polymerase II. Genes Dey 1996, 10: 2657–2683.CrossRefGoogle Scholar
  5. 5.
    Conaway RC, Conaway JW: General transcription factors for RNA polymerase II. Prog Nucleic Acid Res Mol Biol 1997, 56: 327–346.PubMedCrossRefGoogle Scholar
  6. 6.
    Hampsey M: Molecular genetics of the RNA polymerase II general transcriptional machinery. Microbiol Mol Biol Rev 1998, 62: 465–503.PubMedGoogle Scholar
  7. 7.
    Aso T, Conaway JW Conaway RC: The RNA polymerase II elongation complex. FASEB J 1995, 9: 1419–1428.PubMedGoogle Scholar
  8. 8.
    Shilatifard A, Hague D, Conaway RC, Conaway JW: Structure and function of RNA polymerase II elongation factor ELL. Identification of two overlapping ELL functional domains that govern its interaction with polymerase and the ternary elongation complex. J Biol Chem 1997, 272: 22355–22363.PubMedCrossRefGoogle Scholar
  9. 9.
    Shore P, Sharrocks AD: The MADS-box family of transcription factors. Eur J Biochem 1995, 229: 1–13.PubMedCrossRefGoogle Scholar
  10. 10.
    Latchman DS: Transcription factors: an overview. Int J Biochem Cell Biol 1997, 29: 1305–1312.PubMedCrossRefGoogle Scholar
  11. 11.
    Kohn WD, Mant CT, Hodges RS: Alpha-helical protein assembly motifs. J Biol Chem 1997, 272: 2583–2586.PubMedCrossRefGoogle Scholar
  12. 12.
    Tan S, Richmond TJ: Eukaryotic transcription factors. Curr Opin Struct Biol. 1998, 8: 41–48.PubMedCrossRefGoogle Scholar
  13. 13.
    Treisman R: Regulation of transcription by MAP kinase cascades. Curr Opin Cell Biol 1996, 8: 205–215.PubMedCrossRefGoogle Scholar
  14. 14.
    Kaiser K, Meisterernst M: The human general co-factors. Trends Biochem Sci 1996, 21: 342–345.PubMedGoogle Scholar
  15. Darimont BD, Wagner RL, Apriletti JW, et al.: Structure and specificity of nuclear receptor-coactivator interactions. Genes Dey 1998, 12:3343–3356.CrossRefGoogle Scholar
  16. 16.
    Torchia J, Glass C, Rosenfeld MG: Coactivators and co-repressors in the integration of transcriptional responses. Curr Opin Cell Biol 1998, 10: 373–383.PubMedCrossRefGoogle Scholar
  17. 17.
    Hampsey M, Reinberg D: Transcription: why are TAFs essential? Curr Biol 1997, 7: R44 - R46.PubMedCrossRefGoogle Scholar
  18. 18.
    Hahn S: The role of TAFs in RNA polymerase II transcription. Cell 1998, 95: 579–582.PubMedCrossRefGoogle Scholar
  19. 19.
    Struhl K, Moqtaderi Z: The TAFs in the HAT. Ce111998, 94: 1–4.Google Scholar
  20. 20.
    Lee TI, Young RA: Regulation of gene expression by TBP-associated proteins. Genes Dey 1998, 12: 1398–1408.CrossRefGoogle Scholar
  21. 21.
    Ogbourne S, Antalis TM: Transcriptional control and the role of silencers in transcriptional regulation in eukaryotes. Biochem J 1998, 331: 1–14.PubMedGoogle Scholar
  22. 22.
    Boulikas T: Phosphorylation of transcription factors and control of the cell cycle. Crit Rev Eukaryot Gene Expr 1995, 5: 1–77.PubMedGoogle Scholar
  23. 23.
    Hassig CA, Schreiber SL: Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol 1997, 1: 300–308.PubMedCrossRefGoogle Scholar
  24. 24.
    Wade PA, Wolffe AP: Histone acetyltransferases in control. Curr Biol 1997, 7: R82 - R84.PubMedCrossRefGoogle Scholar
  25. 25.
    Wu C: Chromatin remodeling and the control of gene expression. J Biol Chem 1997, 272: 28171–28174.PubMedCrossRefGoogle Scholar
  26. 26.
    Workman JL, Kingston RE: Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem 1998, 67: 545–579.PubMedCrossRefGoogle Scholar
  27. 27.
    Allfrey VG: Structural modifications of histones and their possible role in the regulation of ribonucleic acid synthesis. Proc Can Cancer Conf 1966, 6: 313–335.Google Scholar
  28. Brownell JE, Zhou J, Ranalli T, et al.: Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell 1996, 84:843–851.CrossRefGoogle Scholar
  29. 29.
    Jin S, Scotto KW: Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol 1998, 18: 4377–4384.PubMedGoogle Scholar
  30. 30.
    Armstrong JA, Bieker JJ, Emerson BM: A SWI/SNFrelated chromatin remodeling complex, E-RC1, is required for tissue-specific transcriptional regulation by EKLF in vitro. Cell 1998, 95: 93–104.PubMedCrossRefGoogle Scholar
  31. 31.
    Klein CB, Costa M: DNA methylation and gene expression: introduction and overview. Mutat Res 1997, 386: 103–105.PubMedCrossRefGoogle Scholar
  32. 32.
    Siegfried Z, Cedar H: DNA methylation: a molecular lock. Curr Biol 1997, 7: R305 - R307.PubMedCrossRefGoogle Scholar
  33. 33.
    Razin A: CpG methylation, chromatin structure and gene silencing-a three-way connection. EMBO J 1998, 17: 4905–4908.PubMedCrossRefGoogle Scholar
  34. 34.
    Wolffe A: Packaging principle: how DNA methylation and histone acetylation control the transcriptional activity of chromatin. J Exp Zool 1998, 282: 239–244.PubMedCrossRefGoogle Scholar
  35. 35.
    Nan X, Ng HH, Johnson CA, et al.: Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998, 393:386–389.PubMedCrossRefGoogle Scholar
  36. 36.
    Gonzalgo ML, Jones PA: Mutagenic and epigenetic effects of DNA methylation. Mutat Res 1997, 386: 107–118.PubMedCrossRefGoogle Scholar
  37. Agarwal ML, Taylor WR, Chernov MV, et al.: The p53 network. J Biol Chem 1998, 273:1–4.CrossRefGoogle Scholar
  38. 38.
    Mowat MR: p53 in tumor progression: life, death, and everything. Adv Cancer Res 1998, 74:25–48.PubMedCrossRefGoogle Scholar
  39. 39.
    Taya Y: RB kinases and RB-binding proteins: new points of view. Trends Biochem Sci 1997, 22: 14–17.PubMedCrossRefGoogle Scholar
  40. 40.
    Sellers WR, Kaelin WG, Jr: Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 1997, 15: 3301–3312.PubMedGoogle Scholar
  41. 41.
    Dyson N: The regulation of E2F by pRB-family proteins. Genes Dev 1998, 12: 2245–2262.PubMedCrossRefGoogle Scholar
  42. 42.
    Bergmann L, Maurer U, Weidmann E: Wilms’ tumor gene expression in acute myeloid leukemias. Leuk Lymph 1997, 25: 435–443.Google Scholar
  43. 43.
    Menke AL, van der Eb AJ, Jochemsen AG: The Wilms’ tumor 1 gene: oncogene or tumor suppressor gene? Int Rev Cytol 1998, 181: 151–212.PubMedCrossRefGoogle Scholar
  44. 44.
    Sanchez-Garcia I: Consequences of chromosomal abnormalities in tumor development. Annu Rev Genet 1997, 31: 429–453.PubMedCrossRefGoogle Scholar
  45. 45.
    Facchini LM, Penn LZ: The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J 1998, 12: 633–651.PubMedGoogle Scholar
  46. 46.
    Luque I, Gelinas C: Rel/NF-kappa B and I kappa B factors in oncogenesis. Semin Cancer Biol 1997, 8: 103–111.PubMedCrossRefGoogle Scholar
  47. 47.
    Snowden AW, Perkins ND: Cell cycle regulation of the transcriptional coactivators p300 and CREB binding protein. Biochem Pharmacol 1998, 55: 1947–1954.PubMedCrossRefGoogle Scholar
  48. 48.
    Barr FG: Chromosomal translocations involving paired box transcription factors in human cancer. Int J Biochem Cell Biol 1997, 29: 1449–1461.PubMedCrossRefGoogle Scholar
  49. 49.
    Look AT: Oncogenic transcription factors in the human acute leukemias. Science 1997, 278: 1059–1064.PubMedCrossRefGoogle Scholar
  50. 50.
    Mitani K: Leukemogenesis by the chromosomal translocations. Leukemia 1997, 11 (Suppl 3): 294–296.PubMedGoogle Scholar
  51. 51.
    Grimwade D, Solomon E: Characterisation of the PML/RAR alpha rearrangement associated with t(15;17) acute promyelocytic leukaemia. Curr Top Microbial Immunol 1997, 220: 81–112.CrossRefGoogle Scholar
  52. 52.
    Tenen DG, Hromas R, Licht JD, Zhang DE: Transcription factors, normal myeloid development, and leukemia. Blood 1997, 90: 489–519.PubMedGoogle Scholar
  53. Gelmetti V, Zhang J, Fanelli M, et al.: Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 1998, 18:7185–7191.PubMedGoogle Scholar
  54. Wang J, Hoshino T, Redner RL, et al.: ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human NCoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA 1998, 95:10860–10865.PubMedCrossRefGoogle Scholar
  55. 55.
    Tenbaum S, Baniahmad A: Nuclear receptors: structure, function and involvement in disease. Int J Biochem Cell Biol 1997, 29: 1325–1341.PubMedCrossRefGoogle Scholar
  56. 56.
    Ing NHO, Bert W: The steroid hormone receptor super-family: molecular mechanisms of action. In Molecular Endocrinology: Basic Concepts and Clinical Correlations. 1995: 195–215.Google Scholar
  57. 57.
    Gewirtz AM, Sokol DL, Ratajczak MZ: Nucleic acid therapeutics: state of the art and future prospects. Blood 1998, 92: 712–736.PubMedGoogle Scholar
  58. 58.
    Cavaliieri F: Drugs that target gene expression: an overview. Crit Rev Eukaryot Gene Expr 1996, 6: 75–85.Google Scholar
  59. 59.
    Vasquez KM, Wilson JH: Triplex-directed modification of genes and gene activity. Trends Biochem Sci 1998, 23: 4–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Clary BM, Lyerly HK: Transcriptional targeting for cancer gene therapy. Surg Oncol Clin North Am 1998, 7: 565–574.Google Scholar
  61. 61.
    Maity SN, de Crombrugghe B: Role of the CCAATbinding protein CBF/NF-Y in transcription. Trends Biochem Sci 1998, 23: 174–178.PubMedCrossRefGoogle Scholar
  62. Mantovani R, LaValle E, Bonfani M, et al.: Effect of ecteinascidin (ET-743) on the interaction between transcription factors and DNA. Proc NCI-EORTC 1998, 10:139.Google Scholar
  63. 63.
    Jin S, Gorfajn B, Faircloth G, Scotto KW: Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 2000 [in press].Google Scholar
  64. 64.
    Ly GKA, Schmidt TJ, Pahl HL, Merfort I: The anti-inflammatory sesquiterpene lactone helenin inhibits the transcription factor NF-KB by directly targeting p65. J Biol Chem 1998, 273: 33508–33516.CrossRefGoogle Scholar
  65. 65.
    Singh SNK, Aggarwal BB: Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a potent inhibitor of nuclear transcription factor-kappa B activation by diverse agents. J Immunol 1996, 157: 4412–4420.PubMedGoogle Scholar
  66. 66.
    Warrell R, He L-Z, Richon V, et al.: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998, 90:1621–1625.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine, Inc. 2000

Authors and Affiliations

  • Kathleen W. Scotto
  • Tan A. Ince

There are no affiliations available

Personalised recommendations